|
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application
Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages.
Key Benefits
Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi.
Relatively low regulatory risk because many...
Published: 4/24/2020
Inventor(s): Young-Sup Yoon, Ji Woong Han, Hyunsuk Shim
|
|
Plant-Based Small Molecules for Treatment of MRSA Infections
Application
Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
Key Benefits
Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance.
Does not harm beneficial host bacteria.
May potentially be used concomitantly...
Published: 4/23/2020
Inventor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
|
|
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application
Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries.
Key Benefits
Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries.
Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 4/22/2020
Inventor(s): Ahsan Husain, Nawazish Naqvi
|
|
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application
Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer.
Key Benefits
Novel molecule.
Novel target presents new path to lung cancer treatment.
Potentially extend survival rate of lung cancer patients.
Market Summary
Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020
Inventor(s): Xingming Deng
|
|
Chimeric Molecule for the Treatment of Depression
Application
Small molecules for treating depression and/or depression associated with cancer/chemotherapy.
Key Benefits
Potentially a dual mechanism compound – working via monoamine reuptake inhibition and HDAC inhibition (epigenetic modification).
Quicker acting compound compared to current therapies in the market. Works better than the...
Published: 4/17/2020
Inventor(s): Hyunsuk Shim, Huw Davies, Hyun Min Park, Yoon Hyeun Oum
|
|
Combination Therapy to Treat Pediatric Brain Tumor
Application
Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma.
Key Benefits
Drug combination targets cancer stem cells.
Increased apoptosis of cancer cells compared to current chemotherapeutic agents.
Market Summary
Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 1/28/2020
Inventor(s): Tobey MacDonald, Anna Kenney, James Felker, Abhinav Dey
|
|
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application
System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells.
Key Benefits
Nearly limitless supply of source cells.
Non-invasive method for harvesting source cells.
Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020
Inventor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
|
|
Eradication of Pneumonococcal Carriage with Sodium Deoxycolate
Application
Antibiotic use of sodium deoxycholate for preventing colonization with Streptococcus pneumoniae and treating pneumococcal infection.
Key Benefits
Effective against antibiotic-resistant pneumococcus.
FDA-approved for use in humans.
Safety already demonstrated in FDA trials for subcutaneous injection to dissolve fat deposits in humans.
Market...
Published: 1/22/2020
Inventor(s): Jorge Vidal
|
|
Small Molecule for Treatment-Resistant Lung Cancer
Application
Small molecule agonist for treating cancers involving KRAS mutations.
Key Benefits
Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC).
Selective for mutant KRAS lung cancer cells over normal cells.
Non-toxic to normal cells.
Market Summary
Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020
Inventor(s): Xingming Deng
|
|
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application
GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders.
Key Benefits
Specifically targets NMDARs that contain the GluN2C/2D subunit.
Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators.
Market...
Published: 1/10/2020
Inventor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
|
Emory UniversityOffice of Technology Transfer